Logo image
Back
Prenatal Magnesium Sulfate Exposure and Risk of Cerebral Palsy-Reply
Journal article   Peer reviewed

Prenatal Magnesium Sulfate Exposure and Risk of Cerebral Palsy-Reply

Diana E Schendel, Cynthia J Berg, Marshalyn Yeargin-Allsopp, Coleen A Boyle and Pierre Decoufle
JAMA : the journal of the American Medical Association, v 277(13), pp 1033-1034
02 Apr 1997
DOI: https://doi.org/10.1001/jama.1997.03540370023016
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

In Reply.—Dr Allred and colleagues propose that magnesium sulfate was not a first-line tocolytic in the mid 1980s, but was given almost exclusively for preeclampsia, and that preeclampsia independently contributed to the reduced risk for cerebral palsy in very low-birth-weight infants. For this to be possible, they argue that magnesium sulfate was a marker for both documented and undocumented preeclampsia, since only 45% of the women treated with the drug in our study had documented preeclampsia. Following the example of Allred et al, we examined the concordance among prenatal magnesium sulfate treatment, documented preeclampsia, eclampsia, or hypertension in a woman's medical record, and the same woman's report on interview (yes/no) that she had a hypertensive disorder of pregnancy (toxemia, preeclampsia, hypertension, or seizures caused by pregnancy). Of the 405 (49%) of 833 Atlanta women in our study cohort who were interviewed, 88 (22%) were treated with magnesium sulfate. Forty-five (51%) of

Metrics

5 Record Views

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Pediatrics
Logo image